The MS market in the US is highly fragmented and is quite sticky, so I highly doubt that BG-12 will be able to garner a 50% market share during the next 3-5 years. Copaxone is currently the US market leader with a 40% TRx share (#msg-75407417); Avonex, Rebif, Betaseron, Gilenya, and Tysabri make up the other 60%.
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.